Caladrius Biosciences, Inc. CLBS
Set alert
At close
52-week range unavailable
- Open
- 0.648
- Prev close
- 0.4264
- Mkt cap
- 25.83M
- Vol
- 26.95M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.382
- High
- 0.6497
- Forward P/E
- -1.18
- Beta
- 0.91
- Short ratio
- 2.88
- Inst. own
- 19.50%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2022
- 50-d avg
- 7.53
- 200-d avg
- 9.41
- 1y target
- 4.50
Key statistics
- Market cap
- 25.83M
- Enterprise value
- -41.77M
- Trailing P/E
- 0.00
- Forward P/E
- -1.18
- PEG ratio
- -0.02
- Price / sales
- 0.00
- Price / book
- 0.31
- EPS (TTM)
- -0.394
- Beta
- 0.91
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -15.18M
- Total cash
- 72.99M
- Total debt
- 561.00K
- Return on equity
- -26.31%
- Shares outstanding
- 60.58M
- Short % of float
- 0.81%
- 50-day average
- 7.53
- 200-day average
- 9.41
Analyst view
Consensus: buy
- Target (low)
- 3.00
- Target (mean)
- 4.50
- Target (high)
- 6.00
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 3, 2022
Expected Nov 3, 2022. Consensus EPS estimate -0.12.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2022 | Sep 1, 2022 | -0.12 | — | — | — |
| Aug 4, 2022 | Jun 1, 2022 | -0.10 | — | — | — |
| May 5, 2022 | Mar 1, 2022 | -0.10 | — | — | — |
| Mar 22, 2022 | Dec 1, 2021 | -0.15 | — | — | — |
| Nov 4, 2021 | Sep 1, 2021 | -0.13 | — | — | — |
| Aug 5, 2021 | Jun 1, 2021 | -0.15 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 23, 2022 | HC Wainwright & Co. | main | — | Buy |
| Mar 3, 2021 | Brookline Capital | main | — | Buy |
| May 14, 2019 | WBB Securities | init | — | Speculative Buy |
| Mar 23, 2018 | Chardan Capital | main | Buy | Buy |
| Mar 7, 2018 | H.C. Wainwright | main | Buy | Buy |
| Aug 23, 2016 | Chardan Capital | init | — | Buy |
About Caladrius Biosciences, Inc.
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- caladrius.com
News
- Why Vintage Wine Estates Shares Tumbled 40%; Here Are 70 Biggest Movers From Yesterday
- Stocks That Hit 52-Week Lows On Wednesday
- Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q2 2022 Results - Earnings Call Transcript
- Earnings Scheduled For August 4, 2022
- Caladrius Biosciences to Present at the BIO International Convention 2022
- Caladrius Biosciences to Present at the H.C. Wainwright Global Investment Conference
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates GTYH, CLBS, IGNY, TWTR
- Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q1 2022 Results - Earnings Call Transcript
- Earnings Scheduled For May 5, 2022
- Stocks That Hit 52-Week Lows On Thursday
Your note
Sign in to keep a note on CLBS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BROWN GREGORY B | Director | Stock Award(Grant) | Jan 9, 2022 | 149,040 |
| BUCK KRISTEN K | Officer | Stock Award(Grant) | Aug 31, 2022 | 307,244 |
| DAVIDSON MICHAEL H | Director | Stock Award(Grant) | Jan 9, 2022 | 209,753 |
| FLOWERS CYNTHIA LOUISE | Director | Stock Award(Grant) | Jan 9, 2022 | 145,847 |
| GIROLAMO TODD C. J.D. | Officer | Stock Award(Grant) | Jan 9, 2022 | 165,548 |
| KLOSK STEVEN MARK | Director | Stock Award(Grant) | Jan 9, 2022 | 151,390 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group, Inc. (The) | 4.37% | 2,644,608 | 1.13M | Jun 29, 2022 |
| Sabby Management, LLC | 3.87% | 2,343,991 | 999.48K | Jun 29, 2022 |
| Renaissance Technologies, LLC | 2.68% | 1,623,580 | 692.29K | Jun 29, 2022 |
| Blackrock Inc. | 1.41% | 852,624 | 363.56K | Jun 29, 2022 |
| RA Capital Management, L.P. | 1.24% | 752,500 | 320.87K | Jun 29, 2022 |
| Geode Capital Management, LLC | 0.64% | 390,625 | 166.56K | Jun 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.93% | 1,775,055 | 756.88K | Jun 29, 2022 |
| Vanguard Extended Market Index Fund | 1.40% | 850,585 | 362.69K | Jun 29, 2022 |
| Fidelity Extended Market Index Fund | 0.39% | 237,040 | 101.07K | Jun 29, 2022 |
| Fidelity Series Total Market Index Fund | 0.09% | 51,793 | 22.08K | Jun 29, 2022 |
| Fidelity Total Market Index Fund | 0.08% | 48,949 | 20.87K | Jun 29, 2022 |
| Fidelity NASDAQ Composite Index Fund | 0.05% | 30,152 | 12.86K | Jun 29, 2022 |